Imaginostics
About
Imaginostics is a health tech company developing a quantitative vascular MRI platform (ImagiView™) and AI-powered biomarker engine (ImagiSight™) that transforms standard MRI scanners into precision diagnostic instruments — no new hardware required. From a single scan on existing MRI systems, the platform generates individual-patient maps of microvascular density, blood-brain barrier permeability, and vessel structure. Lead indications include malignant brain neoplasm and Alzheimer's disease. Imaginostics holds FDA Breakthrough Device Designation and a letter of support from Siemens Healthineers, and is backed by the NIH and the Alzheimer's Drug Discovery Foundation.
Imaginostics is the only Biotechnology company we track in Greater Orlando — one of 32 across Florida.
Similar companies
View allASP IsotopesBiotechnology | Est. 2021 | MIA | $372M |
Beacon TherapeuticsBiotechnology | Est. 2023 | GNV | $365M |
SyncromuneBiotechnology | Est. 2020 | MIA | $155M |
Ascend Advanced TherapiesBiotechnology | Est. 2022 | GNV | $131M |
Pasithea TherapeuticsBiotechnology | Est. 2020 | MIA | $104M |
Details
- Region
- Greater Orlando
- City
- Orlando
- Founded
- 2018
- Sector
- Biotechnology
- Founders
- Codi Gharagouzloo, Valerie Gharagouzloo
- Website
- imaginostics.com
Greater Orlando
Central Florida runs on simulation and training, hospitality tech, and a growing Lake Nona life-science cluster, with UCF feeding talent into all three.